throbber

`
`3DownloadedfrominformahealthearecombyMeGillUniversityon01/15/1For
`
`personaluseonly
`
`
`
`
`
`
`
`86
`
`VOLUME 1: FORMULATION AND PACKAGING
`
`(PG), propylene glycol monoester of medium chain fatty acids (Capmul PG),
`glycol
`dimethylsulfoxide (DMSO), and in different combinations of these cosolvents at four different
`temperatures. The degradation of the drug was monitored by HPLC and was found to be
`catalyzed not only by general but also by specific acid and base and followed first-order
`kinetics. The top (time for 90% of the drug remaining intact) in pure cosolvent was 25 50 times
`higher than that in water or semi-aqueous vehicles. Figure 4 shows an Arrhenius plot of
`the observed rate constants of SarCNU in the solvent mixtures. There was no significant
`difference in the slopes for the different solvents, suggesting similar degradation mechanism of
`SarCNU in all solvent mixtures. Furthermore, the order of stabilization by these solvents was
`Capmul PG> /EtOH> /PE> /PG> /WPE> /water, which was in agreement with decreasing
`the polarities of the vehicles. The greatest SarCNU stability, as measured by the degradation
`rate constant derived to), was observed with Capmul PG as shownin Table 4. Another example
`where the degradation was significantly reduced in the nonaqueoussolvents is described for
`Eptifibatide, a peptide compound used as an inhibitor of platelet receptor glycoprotein (42).
`The use of cosolvent to help in solubilization may not, however, lead to favorable stability
`outcome at all the times. Trivedi, et al, (43) showed that as the fraction of organic solvents was
`increased, the degradation of zileuton also increased because of the solvolysis of the drug by
`the cosolvents used.
`
`0.000001 Fi
`
`0.1
`
`0.01
`
`0.001
`
`0.0001
`
`0.00004
`
`k(4/hr)
`
`29 3 313233 343536 373839 4
`1000/T
`
`4
`ility
`behavi
`COONU Wikbecoeotae
`ous cosolvent.
`
`f
`
`Table 4 Degradation of SarCNUin the Presence of Various Cosolvent Mixtures
`
`foo (days)
`
`Room temperature
`Refrigeration
`
`Solvent
`(25°C)
`(4°C)
`
`Water
`Water + propylene glycol + EtOH
`DMSO
`Propylene glycol
`Propylene glycol + EtOH
`EtOH
`Capmul PG
`Source: From Ref. 41.
`
`0.25
`0.50
`1.44
`2.92
`3.64
`7.29
`12.50
`
`5.90
`8.96
`19.03
`7718
`89.50
`199.52
`242.57
`
`Regeneron Exhibit 1015.101
`
`

`

`
`
`3DownloadedfrominformahealthearecombyMcGillUniversityon01/15/1For
`
`personaluseonly
`
`
`
`
`
`
`
`FORMULATION DEVELOPMENT OF SMALL AND LARGE VOLUME INJECTIONS
`
`87
`
`Table 5 Examples of Marketed Injectable Products Containing Cosolvent Mixtures
`Generic name Predominant cosalvent(s) in marketed vehicle Trade name
`
`
`Carmustine
`BICNU
`100% ethanol
`Diazepam
`Valium
`Propylene glycol 40%
`Ethyl alcohol 10%
`Propylene glycol 40%
`Ethyl alcohol 10%
`Propylene glycol 60%
`Ethyl alcohol 5%
`Polyethylene glycol 50%
`Propylene glycol 67 75%
`Propylene glycol 30%
`Ethyl alcohol 20%
`Propylene glycol 40%
`Ethyl alcoho! 10%
`Propylene glycol 40%
`Ethyl alcohol 10%
`ALN dimethylacetamide 695
`Cremophor 50%
`Ethyl alcoho! 40%
`Docetaxel Polysorbate 80 100% Taxotere
`
`Source: From Refs. 44 and 45.
`
`Lanoxin
`
`Alkeran
`
`Robaxin
`Terramycin
`Zemplar
`
`Nembutal
`
`Dilantin
`
`Vumon
`
`
`
`Digoxin
`
`Melphalan
`
`Methocabamol
`Oxytetracycline
`Paricalcitol
`
`Phenobarbital Na
`
`Phenytoin Na
`
`Teniposide
`
`Examples of drugs marketed in water-miscible systems include digoxin, phenytoin,
`diazepam and others as shown in Table 5 (44,45). These injections are formulated in a water-
`miscible system containing glycols and alcohol and adjusted to a suitable pH. Other cosolvents
`used in the past
`included glycerin in deslanoside, dimethylacetamide in reserpine and
`dimethylsulfoxide in chemotherapeutic agents undergoing clinical testing. Propylene glycolis
`used most frequently as a cosolvent, generally in concentrations of 40%. Although such
`systemsare stable in individual vials, care must be exercised on administration. For example,
`phenytoin is dissolved as the sodiumsalt in a vehicle containing 40% propylene glycol and
`10%ethanol and adjusted to a pH of 12 with sodium hydroxide. However, if this solution is
`added to a large-volumeIV solution and the pH is lowered to a value close to the pK, of the
`drug (pK,
`= 8.3), precipitation of the drug can occur. This is due to the fact that in aqueous
`systems at pH below 11, the amount of undissociated phenytoin exceeds its solubility.
`To be used as solubility/stability enhancer in injectable products, the cosolvent must
`have certain attributes such as it should be nontoxic, compatibile with blood, nonsensitizing,
`nonirritating and above all physically and chemically stable and inert. Many cosolvent
`formulations contain high concentrations of organic solvent and most are diluted prior to
`injection, however, some may beinjected directly and in that case, care must be taken that the
`rate of injection remains slow.
`
`Surfactants as solubilizers The ability of surfactants to enhance the solubility of otherwise
`poorly water-soluble compounds in aqueous solution is widely known and used in many
`injectable formulations. Surfactants are effective solubilizing agents because of their wetting
`properties and association tendencies as they are able to disperse water-insoluble substances.
`Surfactants are also used very widely in the biotechnology area for otherwise water-soluble
`monoclonal antibodies and other proteins and polypeptides, but the primary goal of using
`surfactant in these products is to minimize hydrophobic interaction related aggregation and
`not necessarily for the enhancement of solubility. This aspect will be discussed in detail in
`other chapters.
`Surfactants can be either nonionic or ionic(i.e., the ability to lower surface tension rests
`with the anion or cation in the molecule). In nonionic surfactants, the head groups contain no
`charged moieties and their hydrophilic properties are due to the presence of hydroxyl groups.
`Nonionic surfactants are most frequently used in pharmaceutical systems because of their
`compatibility with other surfactants, stability, and relatively low toxicity. Some examples of
`
`Regeneron Exhibit 1015.102
`
`

`

`
`
`DownloadedfrominformahealthcarecombyMcGillUniversityon01/15/13For
`
`personaluseonly
`
`
`
`
`
`
`
`88
`
`VOLUME 7: FORMULATION AND PACKAGING
`
`water-soluble nonionic surfactants include long-chain fatty acid analogs suchasfatty alcohols,
`glyceryl esters, and fatty acid esters. Among the most widely used water-soluble nonionic
`surfactants in injectable products are polyethylene oxide (PEO) sorbitan fatty acid esters, or
`Polysorbates.
`In anionic surfactants, the head groups are negatively charged. The most widely used
`anionic surfactants are those containing carboxylate groups, such as soaps, sulfonates, and
`sulfate ions. In cationic surfactants, the head groups are positively charged. Some examples
`include amine and quaternary ammonium salts. Cationic surfactants are not used in
`pharmaceutical systems because of their toxicity since they adsorb readily to cell membrane
`structures in a nonspecific manner, leading to cell lysis (46).
`themselves at polar/nonpolar
`As shown in Figure 5, surfactants typically orient
`interfaces because of the presence of discrete hydrophobic and hydrophilic regions. As the
`bulk concentration of surfactant in solution is increased, the surfactant molecules begin to
`associate into small aggregates called micelles, whereby their hydrophobic regions are
`shielded from aqueous contact by their hydrophilic regions. All surfactant molecules in excess
`of
`that concentration associate into micelles, while the concentration of nonassociated
`surfactant molecules remains nearly constant. The concentration at which such association
`occurs is called critical micelle concentration (CMC). Using soap as a micelle forming
`substance, Lawrence proposed in 1937 that poorly soluble hydrophobic molecules locate in the
`hydrocarbon core of the micelle, while polar molecules would associate with the polar
`end (47). Molecules that contain polar and nonpolar groups align themselves between the
`chains of the micelle with the nonpolar part directed into the central region and the polar end
`extending out into the hydrophilic chains(Fig. 6).
`
`MKuponIZ,
`Pcy £ro
`
`Polyoxyethylene
`Chains
`
`Polar
`Region
`
`Nonionic
`
`lonic
`
`Illustration of spherical orien
`Figure 5
`tations of nonionic and ionic micelles.
`
`Surfactant Molecules
`
`se SMe gle
`Fhe Ate oho
`
`Nonpolar Drugs
`(D
`
`Semipolar Drugs
`@
`
`Polar Drugs
`(oe)
`
`Figure 6 Schematic representation of mechanisms of miceller solubilization.
`
`Regeneron Exhibit 1015.103
`
`

`

`
`
`
`
`useonly
`
`
`
`3DownloadedfrominformahealthearecombyMcGillUniversityon01/13/1Forpersonal
`
`FORMULATION DEVELOPMENT OF SIMALL AND LARGE VOLUME INJECTIONS
`
`89
`
`Table 6 Effect of Surfactants on the Solubility of Furosemide
`
`
`
` Distilled water 0.1 N hydrochloric acid
`
`Total solubility
`(ug/mL)
`41.2
`
`Miceller solubility
`(ug/mL)
`
`Total solubility
`(ug/mL)
`15.0
`
`Miceller solubility
`(ug/mL)
`
`31.2
`45.0
`57.0
`167.0
`705.0
`
`32.5
`45.0
`112.5
`143.7
`792.5
`
`43.7
`43.7
`141.2
`205.0
`980.0
`
`37
`15.7
`125.7
`663.7
`
`37
`71.2
`102.4
`751.2
`
`2.4
`2.4
`100.0
`163.7
`938.7
`
`40.0
`41.1
`50.0
`145.0
`670.0
`
`25.0
`22.5
`725
`137.5
`887.0
`
`15.9
`18.7
`74.0
`160.0
`808.0
`
`26.1
`35.0
`130.0
`655.0
`
`75
`57.5
`122.5
`872.0
`
`0.9
`3.7
`59.0
`145.0
`793.0
`
`Surfactant % (w/v)
`0
`
`Polysorbate 20 (C12)
`0.005
`0.05
`0.5
`1.0
`5.0
`
`Polysorbate 40 (C16)
`0.005
`0.05
`0.5
`1.0
`5.0
`
`Polysorbate 80 (C18)
`0.005
`0.05
`05
`1.0
`5.0
`
`Source: From Ref. 49.
`
`Generally, the solubilization capacity of a same amountof surfactant is high for those
`with lower CMC value. The solubilizing ability of nonionic surfactant toward water-insoluble
`drugs has been extensively studied (48). Akbuga and Gursoy (49) showed howthesolubility of
`furosemide, a very insoluble compound commonly used as diuretic, was dramatically affected
`by the surfactant concentration and alkyl chain length (Table 6).
`The CMCcan be measured by a variety of techniques, for example, surface tension,light
`scattering, osmometry, all of which show a characteristic break point in the plot of the
`Operative property as a function of concentration. Figure 7, a plot of surface tension against
`concentration of surfactant showsa break in the linearity of the curve, indicating the CMC (50).
`Manyfactors such as temperature, pH ofthe solution, electrolytes, and other ingredients affect
`micellization and hence solubilization (51,52). For nonionic surfactants,
`the CMC value
`decreases with increasing temperature whereas for ionic surfactants,
`it
`increases as the
`temperature increases (53). Since the pH can affect the equilibrium between ionized and
`nonionized solute species, it can have an effect on the capacity of micellar solubility as shown
`by Castro et al, for atenolol, nadolol, midazolam and nitrazepam (54). For ionic surfactant
`micelles, electrolyte addition causes a decrease in the CMC resulting in an increase in the
`micellar solubilization capacity (55), whereas in the case of nonionic surfactant, polysorbate 80,
`the solubility of furosemide increases in the presence of sodium chloride because of increased
`micellar packing and micelle volume (56). Other ingredients present in the formulation can
`also have a profound effect on the solubilizing capacity of surfactants. Surfactants may
`precipitate in the presence of some organic additives or micellization may be abolished if high
`enough concentrations of, for example, alcohols are present. Excipients such as phospholipids
`also affect the CMC. Many water-soluble drugs themselves are remarkably surface active: they
`lower the surface and interfacial
`tension of water, promote foaming, and associate into
`micelles, such as antibacterial (hydrochlorides of acridines, benzalkonium chloride, cetylpyr-
`idinium chloride) tranquilizers (hydrochlorides of reserpine and phenothiazine derivatives),
`local anesthetics (hydrochlorides of procaine, tetracaine, dibucaine, and lidocaine), nonnarcotic
`analgesic (propoxyphene hydrochloride) and narcotic analgesic (morphine sulfate and
`meperidine hydrochloride), antimuscarinic drugs (propantheline bromide, methantheline
`bromide, methixene hydrochloride), cholinergic agents (pilocarpine hydrochloride, and other
`
`Regeneron Exhibit 1015.104
`
`

`

`& es
`
`
`
`
`
`
`
`VOLUME 1: FORMULATION AND PACKAGING
`
`Figure 7 Surface tension versus concentration of
`surfactant. Break in the curve denotes CMC.
`Source: From Ref. 50.
`
`90
`
` 8SURFACETENSION,+,dynescm) &
`
`
`
`
`
`
`
`3DownloadedfrominformahealthearecombyMeGillUniversityon01/15/1Forpersonal
`
`useonly
`
`—-400
`
` —200
`—250
`—300
`-323%
`LOG CONCENTRATION, g/100 mi
`
`—I1.50
`
`alkaloidal salts), antihistamines (pyrilamine maleate, tripelennamine hydrochloride, chlorcy-
`clizine hydrochloride, diphenhydramine hydrochloride), anthelmintics (lucanthone hydro-
`chloride), and antibiotics (sodium fusidate, some penicillins, and cephalosporins) (46).
`Selection of surfactant in the injectable products should be based on its safety and
`toxicology profile (LD50,
`tissue tolerance, hemolysis, etc.), solubility of the drug in the in
`surfactant, and drug-surfactant compatibility. Since surfactants act as nonspecific solubilizers,
`stabilizers, emulsifiers and wetting agents, they can also cause toxicity and disrupt normal
`membranestructure. As mentioned earlier, only nonionic surfactants are generally used in
`parenterals because of their relative less destruction to biological membranes. Table 7 lists
`some commonly used surfactants,
`their properties, and examples of marketed injection
`products that contain surfactants for the purpose of solubility enhancement. Polysorbate 80 is
`
`Table 7 List of Some Surfactants in Injectable Products and Their Properties
`
`Injection product (chemical/
`
`
`
` Surfactant Chemical name HLB® value CMC (%wiw) brand/%surfactant)
`
`
`
`
`
`Cremophor
`
`Solutol HS
`
`Pluronic F68
`
`Polyoxyethylated
`castor oil
`
`Polyethylene glycol
`660 hydroxystearate
`Polaxomer
`
`Polysorbates
`
`Tween 80
`
`12 14
`
`14 16
`
`0.02
`
`0.03
`
`Paclitaxel/taxol/52.7
`Tenoposide/vumon/55
`Cyclosporine/sandimmune/65
`Vitamin K /Aqua mephyton/25
`
`>2d
`
`15
`
`04
`
`0.0014
`
`Recombinant Growth
`hormone/accretropin/0.2
`Amiodorone/cordarone/10
`docetaxel/taxotere/100
`Vitamin A palmitate/aquasol A/12
`Amphotericin/fungizone/0.4
`0.08
`16
`Sodium desoxycholate
`
`Sodium dodecyl sulfate Aldesleukin/proleukin/0.018 40 0.03
`
`
`
`“Hydrophilic Lipophilic Balance
`
`Regeneron Exhibit 1015.105
`
`

`

`
`
`
`
`useonly
`
`
`
`3DownloadedfrominformahealthearecombyMeGillUniversityon01/15/1Forpersonal
`
`FORMULATION DEVELOPMENT OF SMALL AND LARGE VOLUME INJECTIONS
`
`91
`
`the most commonly used surfactant and is used in the range from fraction of percent in many
`products to 100%in the case of taxotere injection.
`
`Cyclodextrins as solubilizers Cyclodextrins are oligomers of glucose produced by enzymatic
`degradation of starch. The number of #-1,4-linked glucose units determine the classification
`into x, B, or y cyclodextrins having six, seven, or eight glucose units, respectively (57 59). The
`cyclodextrins exert their solubilizing effect by forming soluble inclusion complexes in aqueous
`solutions. The cyclodextrins are amphipathic (ie.,
`the exterior is hydrophilic due to the
`hydroxy groups oriented on the exterior while the interior is hydrophobic) and can form
`soluble, reversible inclusion complexes with water-insoluble compounds. The unsubstituted
`cyclodextrins are too toxic for parental use but the chemically modified cyclodextrins appear to
`be well tolerated when administered parenterally and have been shownto effectively enhance
`the solubility of several drugs including steroids and proteins (60,61). The solubility of
`alfaxalone, an insoluble anesthetic, was increased by 5000 times to 19 mg/mLin 20%
`hydroxypropyl-f-cyclodextrin (62). Some other examplesof injectables that are currently in the
`market which contain chemically modified cyclodextrin for the purpose of enhancement of
`solubility are: Aripiprazole (Abilify™) (63), ziprasidone (Geodon™) (64) and voriconazole
`(Vfend™) (65) containing sulfobutylether PB cyclodextrin (SBECD), itraconazole (Sporanox™’)
`(66) containing hydroxypropyl]-f-cyclodextrin, and others.
`Having reviewed the factors that govern solubility and solubilization during the
`formulation development of injectable products, the next considerations are the elements of
`formulations.
`
`Types of vehicles
`Aqueous The vast majority of injectable products are administered as aqueous solutions
`because of the physiological compatibility of water with body tissues. Additionally, the high
`DC of water makes it possible to dissolve ionizable electrolytes, and its hydrogen-bonding
`potential facilitates the solution of alcohols, aldehydes, ketones, and amines. The current USP
`(1) has monographs for purified water, sterile purified water, WFI, sterile WFI, bacteriostatic
`WEI, sterile water for inhalation, and sterile waterfor irrigation.
`WFIis the solvent of choice for making parenterals. It must be prepared fresh and be
`pyrogen-free. It must meet all the chemical requirements for sterile purified water and in
`addition the requirements for bacterial endotoxins. The tests required for WFI are generally the
`same amongthe various pharmacopeias but differences do exist with regards to limits. WFI may
`be prepared byeither distillation or reverse osmosis but the distillation method is by far the most
`common and accepted method. Because of the excellent solvent properties of water,it is both
`difficult to purify and maintain purity. Microorganisms, dissolved gases, organic and inorganic
`substances, and foreign particulate matter are the most common contaminants of water.
`Prior to distillation,
`the water used as the source for WFI is usually subjected to
`chlorination, carbon treatment, deionization, and, sometimes, reverse osmosis treatment (forced
`passage through membrane materials). After distillation, it is filtered and then stored in a
`chemically resistant tank (stainless steel, glass, or blocked tin) at a cold temperature around 5°C
`or at an elevated temperature between 65°C and 85°C to inhibit microbial growth and prevent
`pyrogen formation. Generally, the hot wateris continually circulated in the manufacturing areas
`during storage and usually filtered again prior to use. Sterile WFI and Bacteriostatic WFI are
`permitted to contain higherlevels of solids than WFI becauseof the possible leaching of glass
`container constituents into the water duringsterilization and storage. Bacteriostatic WFI, which
`generally contain 0.9% (9 mg/mL)of benzyl alcohol as a bacteriostatic preservative, should not
`be sold in containers larger than 30 mLto preventinjection of unacceptably large amounts of
`bacteriostatic agents (such as phenol and thimerosal).
`Other water-miscible cosolvents These have been discussed earlier.
`
`Nonaqueous vehicles Drugsthat are insoluble in aqueous systems are often incorporated in
`metabolizable oils. Steroids, hormones, and vitamins are incorporated in vegetable oils such as
`peanut, sesame, corn, olive, and cottonseed. Oil
`injections are only administered intra-
`muscularly. There are strict specifications for the vegetable oils used in manufacturing
`
`Regeneron Exhibit 1015.106
`
`

`

`
`
`
`
`useonly
`
`
`
`3DownloadedtrominformahealthcarecombyMcGillUniversityon01/13/1Forpersonal
`
`92
`
`VOLUME 1: FORMULATION AND PACKAGING
`
`Table 8 Official Injections Containing Oils as Vehicles
`
`
` USP(1) Oil commonly used
`
`Sesame
`Desoxycorticosterone acetate
`Sesame, cottonseed
`Diethylstilbestrol
`Peanut
`Dimercaprol (suspension)
`Cottonseed
`Estradiol cypionate
`Sesame
`Estradiol valerate
`Sesame
`Estrone
`Poppyseed
`Ethiodized iodine
`Sesame
`Fluphenazine decanoate
`Sesame
`Fluphenazine enanthate
`Sesame
`Hydroxyprogesterone caproate
`Sesame
`Menadione
`Sesame
`Nandrolone decanoate
`Sesame
`Nandrolone phenpropionate
`Vegetable
`Penicillin G procaine (combinations)
`Peanut
`Propyliodone (suspension)
`Cottonseed
`Testosterone cypionate
`Sesame
`Testosterone enanthate
`
`Testosterone propionate Sesame
`
`intramuscular injections. Storage of these preparations is important if stability is to be
`maintained. For example, they should not be subjected to conditions above room temperature
`for extended periods of time. Although the oils used for injections are of vegetable origin,
`federal regulations require that the specific oil be listed on the label of a product, because some
`patients have exhibited allergic responses to certain vegetable oils.
`Sesame oil is the preferred oil for most of the compendial injections formulated withoil.
`is the most stable of the vegetable oils (except
`to light), because it contains natural
`It
`antioxidants. Sesameoil has also been used to obtain slow release of fluphenazine esters given
`intramuscularly (67). Excessive unsaturation of oil can produce tissue irritation. In recent
`years,
`the use of injections in oil has diminished somewhat
`in preference to aqueous
`suspensions, which generally haveless irritating and sensitizing properties. Benzyl benzoate
`may be used to enhancesteroid solubility inoils if desired. Table 8 lists the oil injections official
`in the current USP (1).
`
`Added Substances
`Added substances such as buffers, antioxidants, antimicrobial preservatives, tonicity adjusting
`agents, bulking agents, chelating agents, solubilizing agents, and surfactants must frequently
`be incorporated into parenteral formulas in order to provide safe, efficacious, and elegant
`parenteral dosage forms. However, any such additive may also produce negative effects such as
`loss of drug solubility, activity, and/or stability. Any additive to a formulation mustbejustified
`by a clear purpose and function. No coloring agent may be added, solely for the purpose of
`coloring the finished preparation, intended for parenteral administration (1). The readeris
`encouraged to refer to a number of publications that provide comprehensive listing of
`formulation components used in all marketed injectable products (1,68 74). Hospital
`pharmacists who are involved in IV additive programs should be aware of the types of
`additives present in products that are being combined. Commonly used parenteral additives
`and their usual concentrations are listed in Table 9.
`Pharmacopeias often specify the type and amountof additive substances that may be
`included in injectable products. These requirements often vary from compendia to compendia,
`so it is important to refer to the specific pharmacopeia that applies to the product in question.
`USP (1) specifies following maximum limits in preparations for injection that are administered
`in a volume exceeding 5 mL: for agents containing mercury and the cationic surface-active
`compounds, 0.01%; for chlorobutanol, cresol, phenol, and similar types of substances, 0.5%;
`and for sulfur dioxide, or an equivalent amountof the sulfite, bisulfite, or metabisulfite of
`
`Regeneron Exhibit 1015.107
`
`

`

`
`
`
`
`useonly
`
`
`
`3DownloadedfrominformahealthcarecombyMcGillUniversityon01/13/1Forpersonal
`
`FORMULATION DEVELOPMENT OF SIMALL AND LARGE VOLUME INJECTIONS
`
`93
`
`0.01
`0.01
`12
`0.25 0.5
`0.1 0.3
`0.1 0.3
`0.5
`0.002
`0.18
`0.02
`0.015
`0.01
`
`Table 9 Commonly Used Parenteral Additives and Their Usual Concentration
`Added substance
`Usual concentrations (%)
`Antibacterial preservatives
`Benzalkonium chloride
`Benzethonium chloride
`Benzyl alcohol
`Chlorobutanol
`Chlorocresol
`Metacresol
`Phenol
`Phenylmercuric nitrate and acetate
`Methyl p hydroxybenzoate
`Propyl p hydroxybenzoate
`Butyl p hydroxybenzoate
`Thimerosal
`Antioxidants
`Acetone sodium bisulfite
`Ascorbic acid
`Ascorbic acid esters
`Butylhydroxyanisole (BHA)
`Butylhydroxytoluene (BHT)
`Cysteine
`Nordihydroguaiaretic acid (NDGA)
`Monothioglycerol
`Socium bisulfite
`Sodium metabisulfite
`Tocopherols
`Glutathione
`
`0.2
`0.01
`0.015
`0.02
`0.02
`0.5
`0.01
`0.5
`0.15
`0.2
`0.5
`0.1
`
`0.01 0.075
`0.01 0.075
`
`Chelating agent
`Ethylenediaminetetraacetic acid salts
`DTPA
`Buffers
`Acetic acid and a salt, pH 3.5 5.7
`Citric acid and a salt, pH 2.5 6
`Glutamic acid, pH 8.2 10.2
`Phosphoric acid salts, pH 6 8.2
`Tonicity adjustment
`455
`Dextrose
`0.5 0.9
`Socium chloride
`
`Mannitol 45
`
`12
`145
`12
`0.8 2
`
`potassium or sodium, 0.2%. Ethylenediaminetetraacetic acid derivatives and salts are
`sometimes used to complex and thereby inactivate trace metals that may catalyze oxidative
`degradation of drugs. The properties and function of these added substances will be reviewed
`next, except solubilizing agents and surfactant, which have been reviewed earlier.
`
`Buffers. Maintenance of appropriate pH of the formulation is essential for proper solubility
`and stability. Changes in the pH of a formulation may occur during storage because of
`degradation reactions within the product, interaction with container components(i.e., glass or
`rubber), and absorption or evolution of gases and vapors. Buffers are added to many products
`to resist a change in pH. Excellent reviews on pH control within pharmaceutical systems by
`Flynn(75) and Nemaetal (76) are recommended to the reader. A suitable buffer system should
`have an adequate buffer capacity to maintain the pH of the product at a stable value during
`storage, while permitting the body fluids to adjust the pH easily to that of the blood following
`administration. Therefore, the ideal pH to select would be 7.4, the pH of the blood. Extreme
`deviation from this pH can cause complications. Tissue necrosis often occurs above pH 9,
`while extreme pain and phlebitis are experienced below pH 3. The acceptable range for IV
`injections is 3 to 9 because blooditself is an excellent buffer and can very quickly neutralize the
`
`Regeneron Exhibit 1015.108
`
`

`

`94
`
`VOLUME 1: FORMULATION AND PACKAGING
`
`g
`
`Bc4‘
`
`>ia
`
`ee
`
`OFPENICILLIN
`
` RATE OF DEGRADATION
`
`pH
`
`Solubility/stability pH profile of pro
`Figure 8
`caine penicillin. Source: From Ref. 77.
`
`pH outside of 7.4. Parenterals administered by other routes are generally adjusted to a pH
`between 4 and 8.
`A suitable buffer system can be selected from knowledgeof a solubility/stability pH
`profile of the drug in solution. A typical pH profile of both solubility and stability is shown
`in Figure 8 for procaine penicillin G (77). By following the degradation over a given pH range
`and plotting the rate constants versus pH, the pH of maximum stability (pH 6.6) can be
`determined. In the case of procaine penicillin G, the solubility is lowest between the pH 6
`and 7, which is desirable since the product is formulated as a suspension. Once the desired pH
`is determined, a buffer system that provides sufficient buffer capacity can be selected. The
`buffer capacity, B, is an indication of the resistance to change in pH uponthe additionofeither
`basic or acid substances and can be represented by the following expression:
`
`K,H!
`dB
`== 22080
`ape OCR
`
`B
`
`1
`(11)
`
`where
`
`dB = change in concentration of base or acid,
`dpH =
`change in pH,
`C = molar concentration of buffer system, and
`K, = dissociation constant of the buffer.
`
`A hypothetical plot of B versus pH-pK,is illustrated in Figure 9 for a monobasic acid. A
`maximum value at zero indicates that the greatest buffer capacity occurs at a pH equal to the
`pK,of the buffer system and further suggests that a buffer system with a pK, within +1.0 unit
`of the desired pH should beselected.
`Buffer systems for parenterals generally consist of either a weak base and the salt of a
`weak base or a weak acid and the salt of a weak acid. Figure 10 showsthe effective range of
`typical pharmaceutical buffers. The distance indicated by the arrows represents the effective
`buffer range for each system andthe dashed lines represent the pK,for the system. Commonly
`used buffers are phosphates, citrate, acetate, and glutamates.
`The Henderson-Hasselbach relationship is used to calculate the quantities of buffer
`species required to provide a desired pH.
`
`salté
`pH = pK, + logo
`acid
`
`(12)
`
`Regeneron Exhibit 1015.109
`
`
`
`3DownloadedfrominformahealthcarecombyMcGillUniversityon01/13/1For
`
`personaluseonly
`
`
`
`
`
`
`
`

`

`
`
`
`
`useonly
`
`
`
`3DownloadedfrominformahealthcarecombyMcGillUniversityon01/13/1Forpersonal
`
`FORMULATION DEVELOPMENT OF SMALL AND LARGE VOLUME INJECTIONS
`
`95
`
`2
`
`-1
`
`0.0
`
`+1
`
`+2
`
`+3
`
`pH. pkg
`
`Figure 9 Theoretical buffer capacity curves
`of a monobasic acid.
`
` <3
`
`
`CITRATE
`
`
`pK, =3.14
`pK, (2): 4.8
`
`pK, (3): 5.2
`
`pK, (1)= 2.19
`3.0
`pK, (2)= 4.25
`
`
`
`Effective range of pharma
`Figure 10
`ceutical buffers, indicated by the arrows.
`The dashed line represents the pk,
`value.
`
`Where Cys and Cagq are the molar concentrations of the salt form and the acid form,
`respectively. As shown from the following calculation, an acetate buffer system (pK, = 4.8)
`consisting of 0.1 M acetic acid and 0.05 M sodiumacetate would result in a pH of 4.5.
`
`pH - 48 + logo. -4.8 03=45
`Although buffers assure the stability of pH of solution, the buffer system itself can affect other
`properties such as reaction kinetics and solubility aspects. Buffers can act as general acid or
`general base catalysts and cause degradation of some drug substances. Such a mechanism occurs
`with a number of amine and amine derivative drugs in systems containing polycarboxylic
`acids(e.g., citric, tartaric, and succinic). In one such case, as shownin Figure 11, the degradation
`of vitamin B, increases with increase in citrate buffer concentration (78).
`The ionic strength contributions of the buffer system can also affect both isotonicity and
`stability. For example, if adjustment of pH is made with sodium hydroxide, say of a solution
`
`Regeneron Exhibit 1015.110
`
`

`

`96
`
`VOLUME 1: FORMULATION AND PACKAGING
`
`0.100
`
`0.075
`
`0.050
`
`0.025
`
`pH
`7 5.20
`+— 460
`
`4+ 440
`
`«+ 4.00
`
`+— 3.60
`
`+ 3.00
`
`+— 2.50
`
`i
`* ho
`
`= u
`
`l&
`
`= q
`
`i™
`
`0.000
`
` Figure 11 Effect of citrate buffer concentration
`
`Fe
`i
`J
`1
`;
`on thiamine hydrolysis (vitamin B1) at 96.4°C at
`constant ionic strength and atdifferent pH values.

`pam: Tee Se GS Bee
`TOTAL CITRATE (moi/liter)
`Source: From Ref. 78.
`
`containing monosodium phosphate,the effect of the generation of disodium salt on isotonicity
`and the effect of HPO,~* mustbe taken into account(79,80).
`
`Antioxidants. Manydrugsin solution are subject to oxidative degradation. Such reactions are
`mediated either by free radicals or by molecular oxygen and often involve the addition of
`oxygen or the removal of hydrogen. For products in which oxygenis directly involved in the
`degradation, protection can be afforded by displacing oxygen (air) from the system. This is
`accomplished by bubbling nitrogen, argon, or carbon dioxide through the solution prior to
`filling and sealing in the final container. Oxidative decomposition is catalyzed by metal,
`hydrogen, and hydroxyl
`ions. Drugs possessing a favorable oxidation potential will be
`especially vulnerable to oxidation. For example, a great number of drugs are formulated in
`the reduced form (e.g., epinephrine, morphine, ascorbic acid, menadione, etc.) and are easily
`oxidized. Oxidation can be minimized by increasing the oxidation potential of the drug.
`Asillustrated in Figure 12 (81), lowering the pH of the solution will increase the oxidation
`potential. This occurs because according to a simplified version of the Nernst equation:
`
`[H*]- [Ox|
`RT,
`E = E° +— log
`(13)
`[Ral]
`D
`an increase in hydrogen ion concentration causes an increase in the actual oxidation potential,
`E. In this equation E° is the standard oxidation potential, R the gas constant, T the absolute
`temperature, and constant 2 represents the numberof electrons taking part in the oxidation-
`reduction reaction.
`Agents that have a lower oxidation potential than the drug in question, and thus can be
`preferentially oxidized, are called antioxidants. Such agents are added to parenteral solutions
`either alone or in combination with a chelating agent or other antioxidant and function in at
`least two ways: (i) by being preferentially oxidized and thereby gradually consumedor(ii) by
`blocking an oxidative chain reaction in which they are not usually consumed.
`Morphine in aqueous solution undergoes a pH-dependent oxidative degradation. The
`rate is slow and constant between pH 2 and 5, where morphine exists in the protonated formas
`
`Regeneron Exhibit 1015.111
`
`
`
`3DownloadedfrominformahealthcarecombyMcGillUniversityon01/13/1For
`
`personaluseonly
`
`
`
`
`
`
`
`

`

`FORMULATION DEVELOPMENT OF SMALL AND LARGE VOLUME INJECTIONS
`
`97
`
` Figure 12 Relationship between oxida
`
`Y ia
`n
`‘
`4
`4
`i
`RELATION BETWEEN OXIDATION POTENTIAL AND pH
`
`tion potential and pH. Source: From
`Ref. 81.
`
`-=13
`
`-=15
`
`-L.7
`
`S#
`
`-19
`
`aa
`1)
`=£ 2.1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`pH
`
`Figure 13° Reaction rate constant for the first
`order oxidative degradation of morphine at 95°C as
`a function of pH. Source: From Ref. 82.
`
`4 2
`
`,5
`
`“2.7
`
`29
`
`¢:
`
`shown in Figure 13. However, above pH 5, the oxidation increases with increase in pH (82).
`Therefore, morphine canbe stabilized by lowering the pH or by adding an antioxidant such as
`ascorbic acid which will be preferentially and reversibly oxidized between pH 5 and 7.
`Ascorbic acid, in turn, can act as an antioxidant for hydroquinone because it has a lower
`oxidation p

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket